CRISPR Therapeutics Proposes New Appointment to the Board of Directors
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit
CRISPR Therapeutics Announces $280 Million Registered Direct Offering
View All Press
CRISPR Therapeutics is not responsible for the content or availability of third-party sites.
Continue